Summary

Europe Antidepressant Drugs Market is valued approximately USD 4.50 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 2.85% over the forecast period 2024-2032. Antidepressant drugs are medications designed to alleviate symptoms of depression. They work by influencing the balance of neurotransmitters in the brain, chemicals that transmit signals between nerve cells. These medications can help alleviate symptoms of depression, such as persistent sadness, lack of interest in activities, and difficulty concentrating, although their effectiveness and side effects can vary among individuals. Furthermore, rising awareness and reduced stigma surrounding mental health issues. This has led to increased diagnosis and treatment of conditions such as major depressive disorder, anxiety disorders, and other mood disorders. Government initiatives and policies focused on mental health are gaining attraction towards Europe Antidepressant Drugs Market.

The Europe Antidepressant Drugs Market is driven by increasing prevalence of mental health disorders such as depression and anxiety is a significant driver, as more individuals seek medical treatment for these conditions. Moreover, rising advancement in pharmaceutical research and development is also fueling the market growth, as this would lead to rise the introduction of new and more effective antidepressant drugs positively impacting the growth. Furthermore, the aging population in Europe, which is more susceptible to mental health issues across the region. However, side effects associated with antidepressant medications and Stringent regulations and the lengthy approval process for new antidepressant drugs is going to impede the overall demand for the market during the forecast period 2024-2032.

The key countries considered for the Europe Antidepressant Drugs market study includes UK, Germany, France, Italy, Spain, and Rest of Europe. In 2023, Germany was the largest regional market in terms of revenue. The country has a well-established system for diagnosing and treating mental health conditions, supported by both public and private healthcare providers. Additionally, Germany's significant investment in healthcare and pharmaceutical research fosters the development and availability of innovative antidepressant medications. The presence of major pharmaceutical companies and research institutions in Germany also contributes to the country's leading position, as they drive advancements and ensure a steady supply of new and effective treatments. Furthermore, the market in UK, on the other hand, is expected to develop at the fastest rate over the forecast period 2024-2032.

Major market player included in this report are:
GlaxoSmithKline plc
AstraZeneca
Mallinckrodt
Novartis AG
Endo Pharmaceuticals plc
Company 6
Company 7
Company 8
Company 9
Company 10
The detailed segments and sub-segment of the market are explained below:

By Product
Tricyclic Antidepressants
Selective Serotonin Reuptake Inhibitors
Serotonin Norepinephrine Reuptake Inhibitors
Monoamine Oxidase Inhibitors
Serotonin Antagonist and Reuptake Inhibitors
Others

By Depressive Disorders:
Major Depressive Disorder
Obsessive-Compulsive Disorder
Generalized Anxiety Disorder
Panic Disorder
Others
By Region:
Europe
UK
Germany
France
Spain
Italy
ROE

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

ページTOPに戻る

Table of Contents

Chapter 1. Europe Antidepressant Drugs Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. Europe Antidepressant Drugs Market Size & Forecast (2022- 2032)
2.2. Regional Summary
2.3. Segmental Summary
2.3.1. By Product
2.3.2. By Depressive Disorder
2.4. Key Trends
2.5. Recession Impact
2.6. Analyst Recommendation & Conclusion
Chapter 3. Europe Antidepressant Drugs Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. Europe Antidepressant Drugs Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Europe Antidepressant Drugs Market Size & Forecasts by Product 2022-2032
5.1. Tricyclic Antidepressants
5.2. Selective Serotonin Reuptake Inhibitors
5.3. Serotonin Norepinephrine Reuptake Inhibitors
5.4. Monoamine Oxidase Inhibitors
5.5. Serotonin Antagonist and Reuptake Inhibitors
5.6. Others
Chapter 6. Europe Antidepressant Drugs Market Size & Forecasts by Depressive Disorder 2022-2032
6.1. Major Depressive Disorder
6.2. Obsessive-Compulsive Disorder
6.3. Generalized Anxiety Disorder
6.4. Panic Disorder
6.5. Others
Chapter 7. Europe Antidepressant Drugs Market Size & Forecasts by Country 2022-2032
7.1. U.K. Antidepressant Drugs Market
7.1.1. Product breakdown size & forecasts, 2022-2032
7.1.2. Depressive Disorder breakdown size & forecasts, 2022-2032
7.2. Germany Antidepressant Drugs Market
7.3. France Antidepressant Drugs Market
7.4. Spain Antidepressant Drugs Market
7.5. Italy Antidepressant Drugs Market
7.6. Rest of Europe Antidepressant Drugs Market
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.1.1. Company 1
8.1.2. Company 2
8.1.3. Company 3
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. GlaxoSmithKline plc
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. AstraZeneca
8.3.3. Mallinckrodt
8.3.4. Novartis AG
8.3.5. Endo Pharmaceuticals plc
8.3.6. Company 6
8.3.7. Company 7
8.3.8. Company 8
8.3.9. Company 9
8.3.10. Company 10
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes